CAS: 1030612-90-8; 2-(5-(3-(4-(2-Bromo-5-Fluorophenoxy)Piperidin-1-yl)Isoxazol-5-yl)-2H-Tetrazol-2-yl)Acetic Acid
该化合物是一个化学化合物,主要因其潜在的治疗应用,特别是在肿瘤学领域,受到调查,被归类为小分子,并被视为某些生物途径的选择性抑制剂,这可能有助于其针对特定类型的癌症细胞的功效;该化合物展示了独特的分子结构,使其能够与细胞信号和扩散中的具体蛋白进行互动;MK-8245经过了不同阶段的临床试验,以评估其安全性,可耐性和治疗特定恶性的效果;与许多调查药物一样,其药理基因特性,包括吸收,分布,新陈代谢和排泄,对于了解其潜在的治疗窗口和副作用至关重要;正在进行的研究继续阐明其行动机制,并优化其在临床环境中的使用.
- 英文名称2-(5-(3-(4-(2-Bromo-5-Fluorophenoxy)Piperidin-1-yl)Isoxazol-5-yl)-2H-Tetrazol-2-yl)Acetic Acid
- 中文名称2H-四唑乙酸,5-[3-[4-(2-溴-5-氟苯氧基)-1-哌啶基]-5-异恶唑]-
- IUPAC名称2-(5-(3-(4-(2-bromo-5-fluorophenoxy)piperidin-1-yl)isoxazol-5-yl)-2H-tetrazol-2-yl)acetic acid
- 其它别名5-[3-[4-(2-Bromo-5-Fluorophenoxy)-1-Piperidinyl]-5-Isoxazolyl]-2H-Tetrazole-2-Acetic Acid; 2-(5-(3-(4-(2-Bromo-5-Fluorophenoxy)Piperidin-1-yl)Isoxazol-5-yl)-2H-Tetrazol-2-yl)Acetic Acid; ]-2H-Tetrazol; ]-5-Isoxazol; 5-[3-[4-(2-Bromo-5-Fl
- CAS编号1030612-90-8
- MFCD编号:MFCD20039622
- FDA UNII编号:537E7QE8LX
- 分子式:C17H16BrFN6O4分子量:467.26
- 产品CID: 64114
- 同类组份化合物CAS1415559-41-9 (TFA)1030612-90-8 (free base)
- 产品分类生物化工 → 抑制剂 → 代谢(Metabolism)
物理性质
上下游产品
ethyl (5-{3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazol-5-yl}-2H-tetrazol-2-yl)acetate 4-(2-bromo-5-fluorophenoxy)piperidine ethyl 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylate 3-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]isoxazole-5-carboxylic acid amide合成工艺路线路线简述
- 合成目标产物 Mk8245 主要起始原料 4-Hydroxypiperidine
- (文献来源)合成步骤主要原料 4-Hydroxypiperidine
📜1-溴-2,4-二氟苯置于甲酸,Sodium Azide,Potassium Tert-Butylate,三乙胺,Zinc(II) Oxide,Sodium Hydroxide体系中,用 四氢呋喃,2-甲基四氢呋喃,水 用作溶剂,化学反应 34.92H,反应生成2H-四唑乙酸,5-[3-[4-(2-溴-5-氟苯氧基)-1-哌啶基]-5-异恶唑]-
参考文献:Development Of A Practical Synthesis Of Stearoyl-Coa Desaturase (Scd1) Inhibitor Mk-8245
标题:Development Of A Practical Synthesis Of Stearoyl-Coa Desaturase (Scd1) Inhibitor Mk-8245
摘要:A Practical Kilogram Scale Chromatography-Free Synthesis Of Stearoyl-Coa Desaturase 1 (Scd1) Inhibitor Mk-8245 Is Described. The Key Features Of This Sequence Include An Efficient Addition Elimination Reaction Of A Piperidine Fragment With A 3-Bromoisoxaline Followed By An Iodine-Mediated Oxidation To The Corresponding Isoxazole. The Development Of A Safe And Scalable Tetrazole Formation Protocol Is Also Presented.
Doi:10.1021/op200186D
海关参考信息
- 2905199090-其他饱和一元醇
2905399099-其他二元醇
2905499000-其他多元醇
2905590090-其他无环醇的卤化、磺化等衍生物 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-8063224-B2
优先权日:2006-12-01
标 题 :Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
发明人：LACHANCE NICOLAS; LI CHUN SING; LECLERC JEAN-PHILIPPE; RAMTOHUL YEEMAN K
权利人:LACHANCE NICOLAS; LI CHUN SING; LECLERC JEAN-PHILIPPE; RAMTOHUL YEEMAN K; MERCK CANADA INC
摘要:Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Bernabè G, Marzaro G, Shalata MEM, Iosob D, Inglima V, Bellato M, Castagliuolo I, Brun P. Repurposing MK-8245 as a Quorum Sensing Inhibitor to Suppress Virulence and Potentiate Antibiotic Activity in Pseudomonas aeruginosa. Antibiotics (Basel). 2025 Nov 5;14(11):1116. doi: 10.3390/antibiotics14111116.
2: Wu M, Lo TH, Li L, Sun J, Deng C, Chan KY, Li X, Yeh ST, Lee JTH, Lui PPY, Xu A, Wong CM. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (Adgrf1). Elife. 2023 Aug 15;12:e85131. doi: 10.7554/eLife.85131. Erratum in: Elife. 2024 Jan 22;13:e96183. doi: 10.7554/eLife.96183.
3: Hishiki T, Kato F, Nio Y, Watanabe S, Wen Tan NW, Yamane D, Miyazaki Y, Lin CC, Suzuki R, Tajima S, Lim CK, Saijo M, Hijikata M, Vasudevan SG, Takasaki T. Stearoyl-CoA desaturase-1 is required for flavivirus RNA replication. Antiviral Res. 2019 May;165:42-46. doi: 10.1016/j.antiviral.2019.03.002. Epub 2019 Mar 7. 78(19):5548-5560. doi: 10.1158/0008-5472.CAN-17-3964. Epub 2018 Jul 31.
合成参考文献
参考文献:10.1194/jlr.m013177
摘要:Landry F, Chan C, Huang Z, Leclair G, Li CS, Oballa R, Zhang L, Bateman K. Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors. Journal of Lipid Research. 2011 Aug;52(8):1494–9. doi: 10.1194/jlr.m013177.
摘要:S55 | ZINC15PHARMA | Pharmaceuticals from ZINC15 | DOI:10.5281/zenodo.3247749
📝 需求与反馈
尽可能描述清楚需求与问题信息
